Sweden · Delayed Price · Currency is SEK Biovica International AB Earnings Call Transcripts
Fiscal Year 2026
-
Q3 saw 40% year-over-year sales growth, led by Pharma Services and U.S. clinical business momentum. Operating cash flow improved, and the company is focusing on U.S. expansion, new partnerships, and stable costs amid currency volatility.
-
Q2 sales grew 16% year-over-year, with strong momentum in Pharma Services and a solid cash position after a SEK 122 million capital raise. U.S. clinical sales growth flattened but is expected to rebound with new agreements and product launches, while the company targets cash flow positivity in 2027.
-
Revenue grew 50% year-over-year, driven by 72% growth in the US IVD segment and strong Pharma Services momentum. SEK 122 million was raised in a rights issue, supporting expansion and new partnerships, with the company on track for its SEK 50 million fiscal year target.
Fiscal Year 2025
-
Key milestones achieved with strong U.S. and pharma growth, major partnerships, and robust clinical evidence. Revenue guidance set at SEK 50 million for the coming year, with break-even targeted for January 2027. Rights issue to fund U.S. expansion and pharma services.
-
DiviTum's clinical and commercial momentum continues, with strong year-over-year sales growth, expanded partnerships in the U.S. and Europe, and a doubling pharma services pipeline. Liquidity remains a key risk, but new agreements and clinical data are driving increased adoption and interest.
-
DiviTum's clinical and commercial momentum continues, highlighted by strong U.S. and pharma services growth, a major IDN agreement, and expanded clinical validation in both metastatic and adjuvant breast cancer. Cash flow improved, but sales growth lags plan, prompting focus on partnerships and new agreements.
-
DiviTum adoption accelerated in the U.S. with 48% sales growth and increased prescribers, while pharma services saw a 10-11% sequential rise in work order book and a 300% surge in August service testing. Cash flow improved by SEK 8 million, and the company targets cash flow positivity by late 2025.
Fiscal Year 2024
-
Sales grew 115% year-over-year but missed targets, with strong momentum in the U.S. and pharma services. Cost reductions of SEK 30 million annually were implemented, and break-even is targeted for the second half of 2025.